Clinical Immunology Communications最新文献_第9页

Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review 目前治疗阵发性夜间血红蛋白尿的有效性和安全性：一项系统综述

Clinical Immunology Communications Pub Date : 2022-11-23 DOI: 10.1016/j.clicom.2022.11.002

Yara Maria da Silva Pires , Aline de Fátima Bonetti , Jessica Telma Ciecilinsky , Astrid Wiens Souza

{"title":"Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review","authors":"Yara Maria da Silva Pires , Aline de Fátima Bonetti , Jessica Telma Ciecilinsky , Astrid Wiens Souza","doi":"10.1016/j.clicom.2022.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2022.11.002","url":null,"abstract":"<div><p>Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disorder of the pluripotent hematopoietic stem cell. Currently, Eculizumab, Ravulizumab, and Pegcetacoplan are the approved drugs to treat PNH. In order to assess the efficacy and safety of different medications available for PNH, we performed a systematic search. The primary efficacy endpoint was the percentage change in lactate dehydrogenase, transfusion avoidance, and stabilized hemoglobin. Key secondary endpoints included the proportion of patients with breakthrough hemolysis, anemia, adverse events, number of deaths, and discontinuation of treatment. From 2526 articles retrieved from electronic databases and manual searches, a total of five studies were included in this review: 1 observational study and 4 randomized clinical trials. For all efficacy and safety endpoints, Ravulizumab and Pegcetacoplan achieved noninferiority compared with the first standardized treatment Eculizumab. The use of complement inhibition therapy can further improve hematological outcomes in PNH patients.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"3 ","pages":"Pages 37-41"},"PeriodicalIF":0.0,"publicationDate":"2022-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49749438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination “原始抗原原罪”及其与COVID-19疫苗接种的相关性

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.10.001

Ger T. Rijkers , Frans J. van Overveld

{"title":"The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination","authors":"Ger T. Rijkers , Frans J. van Overveld","doi":"10.1016/j.clicom.2021.10.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.10.001","url":null,"abstract":"<div><p>Imprinting of the specific molecular image of a given protein antigen into immunological memory is one of the hallmarks of immunity. A later contact with a related, but different antigen should not trigger the memory response (because the produced antibodies would not be effective). The preferential expansion of cross-reactive antibodies, or T-lymphocytes for that matter, by a related antigen has been termed the original antigenic sin and was first described by Thomas Francis Jr. in 1960. The phenomenon was initially described for influenza virus, but also has been found for dengue and rotavirus. The antibody dependent enhancement observed in feline coronavirus vaccination also may be related to the original antigenic sin. For a full interpretation of the effectivity of the immune response against SARS-CoV-2, as well as for the success of vaccination, the role of existing immunological memory against circulating corona viruses is reviewed and analyzed.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 13-16"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000068/pdfft?md5=e20066a5f3756902be0e724d52936fcf&pid=1-s2.0-S2772613421000068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90027998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia 抗端粒酶免疫反应预测慢性淋巴细胞白血病的疾病进展

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.11.002

Claire Germain , Julie Garibal , Valérie Doppler , Fanny Baran-Marszak , Florence Cymbalista , Julien Caumartin , Pierre Langlade-Demoyen , Maria Wehbe , Thierry Huet

{"title":"Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia","authors":"Claire Germain , Julie Garibal , Valérie Doppler , Fanny Baran-Marszak , Florence Cymbalista , Julien Caumartin , Pierre Langlade-Demoyen , Maria Wehbe , Thierry Huet","doi":"10.1016/j.clicom.2021.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.11.002","url":null,"abstract":"<div><p>Human telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell responses were evaluated by IFNγ-ELISpot. Complementary flow cytometry analyses were performed, and data were analyzed in regards of the treatment received by CLL patients afterward and disease progression. Anti-hTERT responses were more frequently observed in non-progressive watch and wait patients, and in progressive patients scheduled to receive ibrutinib, as compared to patients scheduled to receive other types of treatment. <em>In vitro</em>, addition of the anti-PD-1 antibody nivolumab increased anti-hTERT responses. Importantly, Kaplan Meier analyses showed significantly longer progression-free survival in patients with anti-hTERT immune responses at diagnosis as compared to non-responder patients. Our results show that anti-hTERT T cell responses represent a new potential biomarker predictive of CLL clinical outcome.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 35-44"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000093/pdfft?md5=c5397f4fcad6d6a45e72f2543ca6e890&pid=1-s2.0-S2772613421000093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats 新型普鲁兰小孢子菌AFO-202和N-163在Sprague Dawley大鼠体内产生β葡聚糖的有益免疫调节作用

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.11.001

Nobunao Ikewaki , Kadalraja Raghavan , Vidyasagar Devaprasad Dedeepiya , Suryaprakash Vaddi , Masaru Iwasaki , Rajappa Senthilkumar , Senthilkumar Preethy , Samuel JK Abraham

{"title":"Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats","authors":"Nobunao Ikewaki , Kadalraja Raghavan , Vidyasagar Devaprasad Dedeepiya , Suryaprakash Vaddi , Masaru Iwasaki , Rajappa Senthilkumar , Senthilkumar Preethy , Samuel JK Abraham","doi":"10.1016/j.clicom.2021.11.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.11.001","url":null,"abstract":"<div><p>The beneficial immunomodulation effects of a biological response modifier glucan (BRMG) produced by two strains of Aureobasidium pullulans, AFO-202 and N-163, have already been reported. Herein, we compared their efficacy on immune-inflammatory parameters in Sprague Dawley (SD) rats. This study was performed on four groups of healthy SD rats, n=6 in each group: Group 1, euthanised on Day 0 for baseline values; Group 2, control (drinking water); Group 3, AFO-202 beta glucan, 200 mg/kg/day; and Group 4, N-163 beta glucan, 300 mg/kg/day. The neutrophil to lymphocyte ratio (NLR) decreased and leukocyte-to C-reactive protein ratio (LeCR) increased in Group 3 (AFO-202) at 15 and 29 days whereas the lymphocyte to C-reactive protein ratio (LCR) increased in group 4 (N-163), within the normal physiological range. These promising results warrant further investigations in larger numbers of healthy and diseased models to develop appropriate strategies for balancing immune system dysregulation.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 29-34"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000081/pdfft?md5=e73720ffd1bc8cf7e7a48a584c9882ff&pid=1-s2.0-S2772613421000081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiency 1例古德氏综合征患者和13例常见可变免疫缺陷患者的COVID-19

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.08.003

Hannes Lindahl , C I Edvard Smith , Peter Bergman

引用次数: 2

Antibodies to cytomegalovirus are elevated in myasthenia gravis 重症肌无力患者巨细胞病毒抗体升高

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.09.001

Victoria Probst , Nicole H Trier , Gunnar Houen

{"title":"Antibodies to cytomegalovirus are elevated in myasthenia gravis","authors":"Victoria Probst , Nicole H Trier , Gunnar Houen","doi":"10.1016/j.clicom.2021.09.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.09.001","url":null,"abstract":"<div><p>Myasthenia gravis (MG) is an autoimmune disease characterised by muscular degeneration and autoantibodies to components of the neuromuscular junction. Development of MG is thought to occur from a combination of genetic and environmental factors, and viral infections have been suggested to be involved in the onset of MG through molecular mimicry and/or chronic inflammation. In this work, we analysed sera from MG patients for antibodies to members of the human herpes virus family and other selected pathogens to determine the virus antibody status in the sera of these patients. Enzyme-linked immunosorbent assay, western blotting and line blotting analyses using MG serum pools showed an association between elevated IgG antibody titers to cytomegalovirus (CMV) and MG. These results were replicated using individual serum samples, and showed significant differences in CMV antibody titer between MG patients and healthy controls. Other viruses did not show the same tendency.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 4-12"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000044/pdfft?md5=be60c63673a976739ac868e511587aae&pid=1-s2.0-S2772613421000044-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91723856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of asymptomatic SARS-CoV-2 infection in an Austrian cohort 奥地利人群中无症状SARS-CoV-2感染的流行情况

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.08.002

Elisabeth Mara, Verena Breitsching, Tanja Schuster, Thomas Pekar

{"title":"Prevalence of asymptomatic SARS-CoV-2 infection in an Austrian cohort","authors":"Elisabeth Mara, Verena Breitsching, Tanja Schuster, Thomas Pekar","doi":"10.1016/j.clicom.2021.08.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.08.002","url":null,"abstract":"<div><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged at the end of 2019, causing the coronavirus disease (COVID-19). The main sources of infections are infected and asymptomatic persons. One major problem of the pandemic are the diverse symptoms and the varying manifestations of the illness. In this study, the IgG level recognizing the RBD of SARS-CoV-2 was determined within 336 volunteers from the environment of the University of Applied Sciences Wiener Neustadt. The aims of this study were to identify the estimated number of undiscovered COVID-19 infections and the corresponding antibody levels. In total, 11.3% of the nonvaccinated probands had a positive IgG antibody titer against SARS-CoV-2, whereas 4.0% did not test positive for SARS-CoV-2 or had never been tested at the time of sampling. Probands in this study reported tiredness (57,5%), ageusia/anosmia (55%) and headache (47,5%) as most frequent symptoms.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 17-19"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000032/pdfft?md5=2b80efc2ac0531d8c2aaf3af4e8981dc&pid=1-s2.0-S2772613421000032-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Challenges and insights raised by comorbidity with FMF and selective IgA deficiency FMF和选择性IgA缺乏症的合并症带来的挑战和见解

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.10.002

Leonardo Oliveira Mendonça , Tania Sih , Morton Scheinberg , Daniel Alvarenga , Alex Isidoro Ferreira Prado , Jorge Kalil , Luiz Augusto Marcondes Fonseca , Fabio Fernandes Morato Castro , Myrthes Anna Maragna Toledo Barros , Avi Livneh

{"title":"Challenges and insights raised by comorbidity with FMF and selective IgA deficiency","authors":"Leonardo Oliveira Mendonça , Tania Sih , Morton Scheinberg , Daniel Alvarenga , Alex Isidoro Ferreira Prado , Jorge Kalil , Luiz Augusto Marcondes Fonseca , Fabio Fernandes Morato Castro , Myrthes Anna Maragna Toledo Barros , Avi Livneh","doi":"10.1016/j.clicom.2021.10.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.10.002","url":null,"abstract":"<div><h3>Background</h3><p>: Familial Mediterranean Fever (FMF) is the most common form of genetic autoinflammatory disease worldwide. In turn, selective IgA deficiency (SIgAD) is the most common humoral primary immunodeficiency, yet most patients remain asymptomatic. Case Presentation: A Jewish Brazilian female came to our attention due to recurrent inflammatory febrile episodes since very early in life, initially attributed to unexplained infections linked to SIgAD. At the age of 15 years, disabling buttock pain prompted a sacroiliac MRI, which demonstrated sacroiliitis. Direct genetic sequencing of the MEFV gene confirmed the diagnosis of FMF. After severe gastrointestinal intolerance to colchicine was observed, canakinumab achieved clinical and radiological control, enabling the reinstatement of colchicine. Conclusion: Here we report the first case of concomitant FMF and SIgAD in a Brazilian patient, highlighting the relevance of these comorbidities in the patient's diagnosis and follow-up. This coincidental association also provides insight into interactions between serum and mucosal IgA and the pyrin inflammasome in the control of inflammation and gut dysbiosis.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 25-28"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277261342100007X/pdfft?md5=5501107865079bc0ab3e9d2df349fb86&pid=1-s2.0-S277261342100007X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pfizer–biontech COVID-19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity 在已有自身免疫的患者中，辉瑞生物技术公司的COVID-19 RNA疫苗可诱导磷脂酰丝氨酸自身抗体、冷球蛋白血症和数字坏死

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.08.001

Sandy Nasr, Sara Khalil, Bernard J. Poiesz, Katalin Banki, Andras Perl

{"title":"Pfizer–biontech COVID-19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity","authors":"Sandy Nasr, Sara Khalil, Bernard J. Poiesz, Katalin Banki, Andras Perl","doi":"10.1016/j.clicom.2021.08.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.08.001","url":null,"abstract":"<div><p>We describe a 64-year-old Caucasian female with a history of Raynaud's disease, hand arthritis, photosensitivity, Sjogren's syndrome and leukocytoclastic vasculitis who presented with progressively worsening fingertip necrosis that began three days after receiving a first dose of Pfizer–BioNTech COVID-19 RNA vaccine. Our workup revealed cryoglobulinemia, hypocomplementemia, elevated antinuclear antibodies (ANA) and IgM antiphospholipid autoantibodies (aPL) directed against phosphatidylserine (aPL-PS), suggesting a diagnosis of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The patient failed to develop anti-spike IgG antibodies up to two months following vaccination. Disease progression was halted by plasmapheresis, anticoagulation, and immune suppression. We conclude that the vaccine RNA moiety may induce SLE manifesting in APS, cryoglobulinemia, hypocomplementemia, and digital necrosis.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"1 ","pages":"Pages 1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000020/pdfft?md5=55cb8b8b399fa6ff5b53e5d1526a6349&pid=1-s2.0-S2772613421000020-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91759582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Clinical Immunology Communications: Inaugural Edition 临床免疫学通讯:创刊号

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.06.001

Antonio La Cava (Editor-in-Chief)

引用次数: 0